Trovagene (TROV) says ongoing clinical studies suggest the company's technology is applicable...

|By:, SA News Editor

Trovagene (TROV) says ongoing clinical studies suggest the company's technology is applicable "across a variety of cancer types." The company also announces clinical validation of an assay procedure for the detection of oncogenic mutations in cancer patients' urine. "The … capability to non-invasively monitor a patients' cancer in near-real time may improve … overall [disease] management, leading to better patient outcomes," CEO Antonius Schuh says. Shares +6.5% premarket. (PR)